Skip to main content

Angeles Alvarez Secord

Professor of Obstetrics and Gynecology
Obstetrics and Gynecology, Gynecologic Oncology
Box 3079 Med Ctr, Durham, NC 27710
25172 Morris Bldg, Durham, NC 27710

Overview


My primary research interest has focused on on novel therapeutics, biomarkers and clinical trial development for ovarian and endometrial cancer. My fundamental goal is to develop a strong translational research program at Duke University in the Gynecologic Oncology Division, where knowledge we glean from our basic science research can be incorporated into our clinical trial program. Specifically, my focus is on biologic therapy and molecular biomarkers to direct therapy in patients with ovarian and endometrial cancers to determine if a strategy that incorporates both clinical and genomic information can improve clinical outcome, minimize unnecessary toxicity, and impact positively on quality of life.

In addition I am interested in robotic-assisted laparoscopic surgery for women with endometrial, ovarian and cervical cancers, as well as for benign gynecologic conditions.

Current Appointments & Affiliations


Professor of Obstetrics and Gynecology · 2013 - Present Obstetrics and Gynecology, Gynecologic Oncology, Obstetrics and Gynecology
Member of the Duke Cancer Institute · 1994 - Present Duke Cancer Institute, Institutes and Centers

In the News


Published September 18, 2024
Ovarian Cancer Therapy Trial Shows Promising Results
Published November 8, 2022
Reigniting the White House Cancer Moonshot in Gynecologic & Breast Cancers
Published January 25, 2022
On the Cover: Winter 2022 Duke Ob/Gyn Magazine

View All News

Recent Publications


Genomic alterations, molecularly targeted therapy, and survival: a real-world Endometrial Cancer Molecularly Targeted Therapy Consortium cohort study.

Journal Article Int J Gynecol Cancer · May 2025 OBJECTIVE: Next-generation sequencing and tumor testing to direct therapy in advanced/recurrent endometrial cancer are frequently used, but the impact of this approach is unclear. We sought to confirm the proportion of patients with at least 1 actionable a ... Full text Link to item Cite

The efficacy and safety of mirvetuximab soravtansine in FRα-positive, third-line and later, recurrent platinum-sensitive ovarian cancer: the single-arm phase II PICCOLO trial.

Journal Article Ann Oncol · March 2025 BACKGROUND: Mirvetuximab soravtansine-gynx (MIRV) is a first-in-class, folate receptor alpha (FRα)-targeting antibody-drug conjugate with United States Food and Drug Administration approval for FRα-positive platinum-resistant ovarian cancer. PICCOLO is a p ... Full text Link to item Cite
View All Publications

Education, Training & Certifications


University of Washington · 1994 M.D.